Director Ying Han Resigns from WuXi PharmaTech Co., Ltd. Board

SHANGHAI, July 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Ying Han has stepped down from the WuXi Board of Directors for personal reasons.

Ms. Han has served on WuXi's board since 2008. WuXi has begun a search for a new board member to complete Ms. Han's term of office. The audit committee, of which Ms. Han was chairman, is comprised of Kian-Wee Seah and Xuesong (Jeff) Leng, who have served on WuXi's board since 2005 and 2008, respectively.

"I am very grateful to have had the opportunity to serve on the board of a great company like WuXi since 2008," Ms. Han said. "I have seen the tremendous growth and success of WuXi, and will continue to be a supporter of WuXi's vision to enable anyone and any company to develop healthcare products to benefit patients."

Dr. Ge Li, Chairman and CEO of WuXi PharmaTech, commented, "On behalf of the board, I want to thank Ying for her many years of excellent service as a WuXi board member. All of us at WuXi wish her the very best."

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.